Andrea Riposati started his career at Booz Allen Hamilton as a strategy and management consultant in digital and healthcare. Andrea Riposati holds a Master’s Degree in Business and Economics summa cum laude from Bocconi University and a Master’s Degree in Computer Engineering from the University of Milano-Bicocca. Before founding Dante Labs, Andrea worked in the Healthcare Information Technology sector and focused his efforts on the standardization and development of healthcare IT systems.
Andrea is currently CEO and Co-Founder of Dante Labs, an Artificial Intelligence company that develops tools to facilitate scientific research in three main areas: Computational Neuroscience, Big Data Analysis and Drug Discovery. Andrea is also a Co-Founder at DocVision, an innovative new company that specializes in Ophthalmic Digital Imaging solutions.
Andrea Riposati was born in Milan, Italy. He lives and works in London, UK.
Riposati started his career at Booz Allen Hamilton in 1997 as a strategy and management consultant. He focused on digital healthcare consulting and participated in many health IT projects that led to the launch of several successful products, such as Health Information Exchange (HIE) standards and the Global Patient Safety Net (GPNS). In early 2000s he was instrumental in creating the first standard for healthcare interoperability between multiple legacy EMR systems with OpenMRS.org initiative, a project supported by Booz Allen Hamilton, General Electric and IBM.
Andrea Riposati also contributed to the development of a disruptive new technology, which is now known as “Big Data”, during his time at Booz Allen Hamilton and later at Accenture. He was one of the first to apply this technology in healthcare with a number of different projects, including those for the NHS.
In 2004 Riposati joined Transvision Surgical, a medical technology consulting company in Boston, where he worked as CTO on several digital healthcare projects for large medical device manufacturers. He also participated in developing OraSure Technologies’ next-generation HIV-1 rapid testing system that is currently being used by over 30,000 clinics worldwide.